Clinical Development Update from Portfolio Company LogicBio
As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.
- As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.
- In its letter, the FDA acknowledged that the company satisfactorily addressed all clinical hold issues.
- In connection with the lifting of the clinical hold, LogicBio amended the SUNRISE protocol in a manner that reflected its dialogue with the FDA.
- LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering genome editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood.